251 related articles for article (PubMed ID: 33730896)
1. Evaluation of the diagnostic value of the renal resistive index as a marker of the subclinical development of cardiorenal syndrome in MMVD dogs.
Szczepankiewicz B; Pasławska U; Siwińska N; Plens K; Pasławski R
J Renin Angiotensin Aldosterone Syst; 2021; 22(1):1470320321995082. PubMed ID: 33730896
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease.
Li Q; Larouche-Lebel É; Loughran KA; Huh TP; Suchodolski JS; Oyama MA
J Am Heart Assoc; 2021 May; 10(9):e018923. PubMed ID: 33890477
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
Troia R; Sabetti MC; Crosara S; Quintavalla C; Romito G; Mazzoldi C; Fidanzio F; Cescatti M; Bertazzolo W; Giunti M; Dondi F
J Vet Intern Med; 2022 Nov; 36(6):2053-2062. PubMed ID: 36196592
[TBL] [Abstract][Full Text] [Related]
4. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
[TBL] [Abstract][Full Text] [Related]
5. The urine podocin/creatinine ratio as a novel biomarker of cardiorenal syndrome in dogs due to degenerative mitral valve disease.
Szczepankiewicz B; Paslawska U; Paslawski R; Gebarowski T; Zasada W; Michalek M; Noszczyk-Nowak A
J Physiol Pharmacol; 2019 Apr; 70(2):. PubMed ID: 31356184
[TBL] [Abstract][Full Text] [Related]
6. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
[TBL] [Abstract][Full Text] [Related]
7. Utility of focused cardiac ultrasonography training in veterinary students to differentiate stages of subclinical myxomatous mitral valve disease in dogs.
Huh T; Achilles EJ; Massey LK; Loughran KA; Larouche-Lebel É; Convey V; McKaba VF; Crooks A; Kraus MS; Gelzer AR; Oyama MA
J Vet Intern Med; 2024; 38(3):1325-1333. PubMed ID: 38532734
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
Wolf J; Gerlach N; Weber K; Klima A; Wess G
Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.
Galizzi A; Bagardi M; Stranieri A; Zanaboni AM; Malchiodi D; Borromeo V; Brambilla PG; Locatelli C
BMC Vet Res; 2021 Jan; 17(1):15. PubMed ID: 33413406
[TBL] [Abstract][Full Text] [Related]
10. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
[TBL] [Abstract][Full Text] [Related]
11. Iron parameters analysis in dogs with myxomatous mitral valve disease.
Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
Ames MK; Atkins CE; Eriksson A; Hess AM
J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
[TBL] [Abstract][Full Text] [Related]
13. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
[TBL] [Abstract][Full Text] [Related]
16. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
Boswood A; Gordon SG; Häggström J; Vanselow M; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
J Vet Intern Med; 2020 May; 34(3):1108-1118. PubMed ID: 32200574
[TBL] [Abstract][Full Text] [Related]
17. Effect of sampling time on urinary electrolytes following oral furosemide administration in dogs with myxomatous mitral valve disease.
Sabetti MC; Fidanzio F; Troìa R; Perissinotto L; Romito G; Mazzoldi C; Quintavalla C; Crosara S; Dondi F
J Vet Cardiol; 2022 Jun; 41():57-69. PubMed ID: 35245876
[TBL] [Abstract][Full Text] [Related]
18. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
[TBL] [Abstract][Full Text] [Related]
19. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
[TBL] [Abstract][Full Text] [Related]
20. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
